Negative pregnancy test in women at childbearing age
All patients must have signed an informed consent before study entry.
You may not be if
Known secondary cancer other than curatively treated basalioma or carcinoma in situ of the cervix uteri
Clinically unstable CNS-metastases
Known hypersensitivity against study medication
Severe impairment of renal function (creatinine clearance \< 30 ml/min)
Severe impairment of liver function (bilirubin \> 2,0 x above upper norm, transaminases \> 2,5 x upper norm, or with known liver metastasis \>5 x upper norm)
Clinically relevant disease of the cardiovascular system or other vital organs
Known polyneuropathy
Known DPD-deficiency (screening not required)
Simultaneous treatment with the antiviral agent sorivudin or chemically related agents such as brivudin
Pregnancy, lactation or lack of reliable contraception in women at childbearing age
Mental disease, drug- or alcohol abuse
Participation in another clinical trial within the last 4 weeks
All other diseases which may prevent adequate participation in the trial
Indication of lack of compliance with study regulations
Clareo Health | Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine
